Innovative liquid formulation, based on the excipient technology.

Nasal spray

AQ000N, as reference in the treatment of Nasal Disorders

HP-Betadex Solution can be used alone or combined with different molecules in the treatment of nasal disorders. A significant percentage of patients suffering from nasal diseases remains uncontrolled despite adequate treatment, and surely in Allergic Rhinitis.

The answer to today’s needs in the field of allergic rhinitis medication

Allergic Rhinitis and its Impact on Asthma (ARIA) tries to gives an international consensus to treat patients suffering from AR, INCS being considered as the first-line treatment.

The INCS (Intranasal corticosteroids) cover all AR symptoms that are Nasal congestion/obstruction, rhinorrhoea, itchy nose and/or eyes, and/or sneezing are the symptoms of AR. The overall clinical response does not appear to vary significantly between available INCS, irrespective of the differences in topical potency, lipid solubility, and binding affinity. When giving in recommended doses INCS are not associated with clinically significant systemic side effects.

Because Intranasal corticosteroids are the most effective medication class in controlling the symptoms of allergic rhinitis, Aquilon Pharma’s AQ000N is the key.


Aquilon Pharma has strong patents covering its excipient platform up to 2039. Several patents are granted in most of the key countries around the globe.

Medical advantages

Thanks to the excipient in the AQ000N complex, Aquilon expects to

  • Show prolonged airway activity for the same drug concentration
  • Have a better diffusion in the nasal membrane
  • Be more efficient than existing INCS at lower dose
  • Improve the efficiency of the administration
  • Minimize the risk of side effects and/or drug addiction

Nasal spray

Contact us

Do you have a question? Let's get in touch.